RGEN
REPLIGEN CORP
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$176.89
−0.73%Sep 15, 2026, 20:07 UTC
Karen A. Dawes will retire from the board of directors of Repligen Corp, effective September 30, 2026.
Sep 8, 2026, 22:00 UTC
Repligen and BioLife Solutions received US antitrust approval for their $1.5 billion merger as the Hart-Scott-Rodino waiting period expired on September 3, 2026.
Source:Aug 22, 2026, 07:58 UTC
B. Metzler seel. Sohn & Co. AG acquired a new position of 26,361 shares in Repligen Corporation, valued at approximately $3.60 million, during the second quarter, as disclosed in its SEC filing.
Source:Aug 6, 2026, 20:03 UTC
Repligen announced it will acquire BioLife Solutions, with the transaction expected to close in the fourth quarter of 2026.
Source:Aug 1, 2026, 07:50 UTC
Avidity Partners Management LP increased its stake in Repligen Corporation by 54.7% during the second quarter of 2026, acquiring an additional 27,500 shares, according to a Form 13F filing.
Source:Jul 28, 2026, 11:00 UTC
Repligen Corporation reported financial results for the second quarter of 2026, covering the three-month period ended June 30, 2026.
Jul 22, 2026, 10:00 UTC
Repligen agreed to acquire BioLife Solutions to expand its cell therapy capabilities with biopreservation media.
Jun 27, 2026, 16:20 UTC
BioLife has drawn takeover interest from Repligen.